

MEDICAL PRESCRIPTION FORM



Laboratoire Cerba Customer relation service

Tel.: +33 (0)1 34 40 97 76 Fax: +33 (0)1 34 40 21 29 Email: intgb@lab-cerba.com

HEREDITARY AUTO-INFLAMMATORY DISEASES

| IMPORTANT: CHECK-LIST BEFORE SHIPPING | | | | | | | |
|--|--|--|--|--|--|--|--|
| ☐ Medical prescription | | | | | | | |
| ☐ Attestation and consent forms signed by the patient AND the prescriber (http://www.lab.cerba.com/images/espace_medecin/CONSSG.pdf) | | | | | | | |
| ☐ Clinical form (see other side) | | | | | | | |
| □ PREREQUISITES (according to the national network of AID genetic diagnosis laboratories): | | | | | | | |
| O At least 3 unexplained inflammatory episodes | | | | | | | |
| High C-Reactive Protein (CRP) during an episode (attach test results) O High mevalonaturia during episodes (Mevalonate Kinase Deficiency (MKD) | , , , , , , , , , , , , , , , , , , , | | | | | | |
| COLLECTION LABORATORY | BLOOD SAMPLE (5mL EDTA whole blood at room temperature) | | | | | | |
| Customer: LILIC/LI | Sampling date: | | | | | | |
| Customer: | Time of collection: | | | | | | |
| Stamp | | | | | | | |
| | | | | | | | |
| PATIENT | Prescriber | | | | | | |
| SURNAME | SURNAME | | | | | | |
| FIRST NAME | FIRST NAME | | | | | | |
| Birth name | Address | | | | | | |
| Date of birth | ZIP code Town | | | | | | |
| ZIP code Town | Phone LLL LLL LLL | | | | | | |
| Phone LLL LLL LLL | Fax LLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLL | | | | | | |
| Geographical origin | E-mail address | | | | | | |
| Parental consanguinity ☐ Yes ☐ No ☐ Unknown | | | | | | | |
| Family history of auto-inflammatory syndrome (Crohn's, ulcerative colitis, | | | | | | | |
| Behçet's): | Signature: | | | | | | |
| ☐ Yes ☐ No ☐ Unknown | | | | | | | |
| INDICATION | REQUIRED TEST (CODE NATURE: SGE) | | | | | | |
| ☐ Clinical suspicion | ☐ <i>MEFV</i> gene study (exons 2, 3, 5, 9 and 10) (code OPL : MEFV) | | | | | | |
| □ Familial Mediterranean Fever (FMF) | | | | | | | |
| ☐ TNF receptor 1-associated periodic syndrome (TRAPS) | ☐ TNFRSF1A gene study (exons 2, 3 and 4) (code OPL : TRAPS) | | | | | | |
| ☐ Cryopyrin-associated periodic syndrome (CAPS) | □ NLRP3 gene study (exon 3) (code OPL : CAPS) | | | | | | |
| □ NLRP12-associated hereditary periodic fever syndrome (NAPS12) | NI PP12 gaps study (even 2) (aste OR anapp) | | | | | | |
| | □ NLRP12 gene study (exon 3) (code OPL : NAPS) | | | | | | |
| ☐ Periodic fever syndrome with hyper-Ig D (MKD) | ☐ MVK gene study (exons 2 to 11) (code OPL : MVK) | | | | | | |
| ☐ Family study (attach index case results) | Torgeted childy (MEEV, TNEDSEAA AN DD2 AN DD42 ANW) | | | | | | |
| | ☐ Targeted study (MEFV, TNFRSF1A, NLRP3, NLRP12, MVK gene) | | | | | | |
| | ☐ Known mutation(s): | | | | | | |



MEDICAL PRESCRIPTION FORM



Laboratoire Cerba Customer relation service

Tel.: +33 (0)1 34 40 97 76 Fax: +33 (0)1 34 40 21 29 Email: intgb@lab-cerba.com

HEREDITARY AUTO-INFLAMMATORY DISEASES

| CLINICAL FORM | | | | | | | | |
|---|--------------|--------------|-------------|------------------------|------------|----------|--|--|
| ☐ Triggering factor: ○ Ho | ot O | Cold | O Vaccine | O Stress | ○ Fatigue | | | |
| ☐ Frequency of episodes: ○ <1 | /month O 1 | I-2/months | ○ >2/months | O Chronic | Ounknown | | | |
| □ Duration of episodes: □ Age of first symptoms : □ | | | | | | | | |
| ☐ Inflammation ☐ Gastrointestinal | | | | | | | | |
| ☐ Fever | ○ Yes ○ N | No O Unknown | 1 | ☐ Abcess | ○ Yes ○ No | Ounknown | | |
| ☐ High CRP | ○ Yes ○ N | No O Unknown | 1 | ☐ Hepatomegaly | ○ Yes ○ No | Ounknown | | |
| ☐ Thoracic | | | | ☐ Cytolytic hepatitis | ○ Yes ○ No | Ounknown | | |
| ☐ Pain | ○ Yes ○ N | lo O Unknown | | ☐ Splenomegaly | ○ Yes ○ No | Ounknown | | |
| ☐ Pleuritis-Pericarditis | ○ Yes ○ N | lo O Unknown | | ☐ Diarrhea | ○ Yes ○ No | Ounknown | | |
| □ Pneumopathy | ○ Yes ○ N | lo O Unknown | | ☐ Abdominal pain | ○ Yes ○ No | Ounknown | | |
| ■ Neurosensory | | | | ☐ Hemorrhage | ○ Yes ○ No | Ounknown | | |
| □ VCA/TIA | ○ Yes ○ N | lo O Unknown | | ☐ Vomitting | ○ Yes ○ No | Ounknown | | |
| ☐ Calcification | ○ Yes ○ N | lo O Unknown | ☐ Muc | ocutaneous | | | | |
| ☐ Cephalea | ○ Yes ○ N | lo O Unknown | | ☐ Oral ulcer | ○ Yes ○ No | Ounknown | | |
| ☐ Conjunctivitis | ○ Yes ○ N | lo O Unknown | | ☐ Genital ulcer | ○ Yes ○ No | Ounknown | | |
| □ Encephalitis | ○ Yes ○ N | lo O Unknown | | ☐ Erythema nodosum | ○ Yes ○ No | Ounknown | | |
| ☐ Epilepsy | ○ Yes ○ N | lo O Unknown | | ☐ Folliculitis/Acne | ○ Yes ○ No | Ounknown | | |
| ☐ Meningitis | ○ Yes ○ N | lo O Unknown | | ☐ Lipodystrophy | ○ Yes ○ No | Ounknown | | |
| ☐ Papillitis | ○ Yes ○ N | lo O Unknown | | ☐ Maculopapules | ○ Yes ○ No | Ounknown | | |
| ☐ Intellectual disability | O Yes O N | lo O Unknown | | ☐ Necrosis | ○ Yes ○ No | Ounknown | | |
| ☐ Hearing loss | O Yes O N | lo O Unknown | | □ Edema | ○ Yes ○ No | Ounknown | | |
| ☐ Uveitis | O Yes O N | lo O Unknown | | ☐ Pseudoerysipelas | ○ Yes ○ No | Ounknown | | |
| ☐ Locomotor | | | | ☐ Psoriasis | ○ Yes ○ No | Ounknown | | |
| ☐ Arthralgia | O Yes O N | lo O Unknown | | □ Pyoderma | ○ Yes ○ No | Ounknown | | |
| ☐ Arthritis | ○ Yes ○ N | lo O Unknown | | ☐ Tenosynovitis | ○ Yes ○ No | Ounknown | | |
| ☐ Myalgia | ○ Yes ○ N | lo O Unknown | | ☐ Hives | ○ Yes ○ No | Ounknown | | |
| □ Deforming arthropathy | ○ Yes ○ N | lo O Unknown | | ☐ Vasculitis | ○ Yes ○ No | Ounknown | | |
| ☐ Osteitis | ○ Yes ○ N | lo O Unknown | ☐ Othe | er | | | | |
| Renal | | _ | | ☐ Failure to thrive | ○ Yes ○ No | Ounknown | | |
| ☐ Amyloidosis | ○ Yes ○ N | | | ☐ Adenopathy | ○ Yes ○ No | Ounknown | | |
| ☐ Kidney failure | ○ Yes ○ N | | | ☐ Allergy | ○ Yes ○ No | Ounknown | | |
| ☐ Proteinuria | ○ Yes ○ N | lo O Unknown | | ☐ Recurrent infections | ○ Yes ○ No | Ounknown | | |
| | | | | ☐ Pharyngitis | ○ Yes ○ No | Ounknown | | |
| Togathent | | | | | | | | |
| TREATMENT | | | | | | | | |
| ☐ Colchicine: ○ No | ○ Yes ► Resp | | O Complete | ○ Partial | | | | |
| ☐ Corticoids: ○ No | O Yes ► Resp | onse O No | O Complete | O Partial | | | | |
| □ NSAID: ○ No | ○ Yes ► Resp | onse O No | O Complete | O Partial | | | | |
| ☐ IL-1 inhibitor: ○ No | ○ Yes ► Resp | onse O No | O Complete | O Partial | | | | |
| ☐ TNF inhibitor: ○ No | ○ Yes ► Resp | onse O No | O Complete | O Partial | | | | |